In a recent opinion piece for the DC Journal, several industry experts weighed in on the consensus stance that lawmakers need to stop drug price manipulation driven by pharmacy benefit managers (PBMs).
Authors for this article included Mark Blum, managing director of the PBM Accountability Project and founder of Solidaritus Health; David Mermin, pollster, political strategist and partner at Lake Research Partners; and Christine Matthews, a leading public opinion pollster at Bellwhether Research.
The article focuses on how the anti-consumer practices of these health insurance corporate middlemen are driving up out-of-pocket prescription drug costs, and the fact that recent polling has confirmed the American people want this issue addressed.
In fact, nine-in-10 likely voters say it is important or very important to have rules that will require PBMs to provide value and lower drug costs for consumers. More than two-thirds of these voters say they are likelier to vote for a candidate who supports regulating PBMs.
